Regeneration of oral soft tissue defects, including mucogingival defects associated with the recession or loss of gingival and/or mucosal tissues around teeth and implants, is crucial for restoring oral tissue form, function, and health. This study presents a novel approach using three‐dimensional (3D) bioprinting to fabricate individualized grafts with precise size, shape, and layer‐by‐layer cellular organization. A multicomponent polysaccharide/fibrinogen‐based bioink is developed, and bioprinting parameters are optimized to create shape‐controlled oral soft tissue (gingival) constructs. Rheological, printability, and shape‐fidelity assays, demonstrated the influence of thickener concentration and print parameters on print resolution and shape fidelity. Artificial intelligence (AI)‐derived tool enabled streamline the iterative bioprinting parameter optimization and analysis of the interaction between the bioprinting parameters. The cell‐laden polysaccharide/fibrinogen‐based bioinks exhibited excellent cellular viability and shape fidelity of shape‐controlled, full‐thickness gingival tissue constructs over the 18‐day culture period. While variations in thickener concentrations within the bioink minimally impact the cellular organization and morphogenesis (gingival epithelial, connective tissue, and basement membrane markers), they influence the shape fidelity of the bioprinted constructs. This study represents a significant step toward the biofabrication of personalized soft tissue grafts, offering potential applications in the repair and regeneration of mucogingival defects associated with periodontal disease and dental implants.
IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus and Vero E6 assay with a quadratic optimization workflow. A starting pool of 12 candidate drugs developed in collaboration with a community of infectious disease clinicians was first narrowed down to a six-drug pool and then interrogated in 50 combination regimens at three dosing levels per drug, representing 729 possible combinations. IDentif.AI-x revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived, and pinpointed a number of clinically actionable drug interactions, which were further reconfirmed in SARS-CoV-2 variants B.1.351 (Beta) and B.1.617.2 (Delta). IDentif.AI-x prioritized promising drug combinations for clinical translation and can be immediately adjusted and re-executed with a new pool of promising therapies in an actionable path towards rapidly optimizing combination therapy following pandemic emergence.
A hallmark of subclinical metabolic decline is impaired metabolic flexibility, which refers to the ability to switch fuel utilization between glucose and fat according to energy demand and substrate availability. Herein, we propose optimizing metabolic health with digital twins that model an individual’s metabolic flexibility profile to gamify the process of health optimization and predict long-term health outcomes. We explore key characteristics of this approach from technological and socioeconomical perspectives, with the objective of reducing the burden from metabolic disorders through driving behavior change and early detection of metabolic decline.
Aortic valve stenosis (AVS) is a sexually dimorphic disease where aortic valve leaflets develop fibrosis and calcification, leading to heart failure if untreated. Sex differences in AVS progression depend on valvular interstitial cells (VICs) activating to myofibroblasts that drive aberrant extracellular matrix remodeling. To date, no treatment strategies have leveraged cellular sex differences to determine drug combinations that target VIC myofibroblast activation. Here, we harnessed IDentif.AI, an artificial intelligence (AI)–derived platform, to optimize sex-biased synergistic drug combinations that may prevent and reverse VIC myofibroblast activation on hydrogel biomaterials. The results reveal that sex-specific drug response models can be used to predict sex biases in drug efficacy and combinatorial interactions. This study provides a framework for developing AVS treatments through the integration of high-throughput hydrogel cell culture platforms and AI-driven drug optimization. Designing targeted AVS drug combinations may help accelerate AVS drug development and address health disparities in AVS treatment outcomes.